Roche Holding AG ADR Stock
€45.28
Your prediction
Roche Holding AG ADR Stock
Pros and Cons of Roche Holding AG ADR in the next few years
Pros
Cons
Performance of Roche Holding AG ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Roche Holding AG ADR | -1.080% | 3.171% | 2.152% | 28.678% | 3.310% | 20.695% | 26.451% |
| Novartis AG ADR | 0.770% | 0.000% | 4.839% | 30.000% | 9.705% | 42.544% | 79.063% |
| Bayer AG ADR | -3.630% | -1.064% | -1.587% | 47.619% | 5.682% | -29.008% | -28.462% |
| UCB S.A. | -0.410% | 1.297% | 1.637% | 52.711% | 2.022% | 191.386% | 219.188% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Roche Holding AG (RHHBY), a multinational healthcare company based in Switzerland, stands strong with its broad and diversified portfolio. A closer look into Roche's financial statements prominently reveals a robust business model underpinned by substantial revenues and a profitable margin.
Observing Roche's income statements over the past three years, the figures showcase an impressive gross profit with a steady upward trend. This consistency strongly indicates a robust operating model and proficient managerial efficiency. With increasing net income, the company seems to have experienced notable business and financial growth, reinforcing the credibility of the investment.
Roche also earns recognition for its significant investment in research and development, crucial for pharmaceutical companies. The data reveals a substantial annual expenditure, reflecting Roche's commitment to future growth and revolutionizing pharmaceutical breakthroughs, leading to a sustainable competitive advantage.
Comments
News
President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?
President Trump has made it a priority to address the U.S.'s high drug prices. His administration's Most-Favored-Nation (MFN) policy, centered on the idea that Americans shouldn't have to pay more
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
Key Points
- Interested in Climb Bio, Inc.? Here are five stocks we like better.
- Budoprutug, Climb Bio’s CD19-targeting antibody, is the company’s lead asset, with early data showing complete
Analog Devices Q2 Earnings Call Highlights
Key Points
- Interested in Analog Devices, Inc.? Here are five stocks we like better.
- Analog Devices posted record fiscal Q2 2026 results, with revenue of $3.62 billion, non-GAAP EPS of $3.09